3Q 2017 ASP drug price limits continue upward trend — mostly for high-end drugs
The latest price limit revisions in drug average sales prices (ASP) changes from CMS show a slight uptick from Q2 to Q3 2017, but a one- and a three-year lookback show that trend over the past few years has been toward rising prices.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.